News
Moderna to expand BARDA agreement to support larger phase 3 program for Covid-19 vaccine
BARDA will extend an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the Moderna’s mRNA vaccine candidate (mRNA-1273) against COVID-19.
Delhi’s APAC Biotech bags patent for personalized immunotherapy based cancer treatment
APCEDEN – APAC’s immunotherapy product, has already been approved by the Indian FDA for treating cancer. The company has further announced it will conduct clinical trials for highly aggressive brain tumors
